Creative Financial Designs Inc. ADV Decreases Stock Holdings in Invesco Biotechnology & Genome ETF $PBE

Creative Financial Designs Inc. ADV trimmed its holdings in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 32.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,971 shares of the company’s stock after selling 1,448 shares during the quarter. Creative Financial Designs Inc. ADV’s holdings in Invesco Biotechnology & Genome ETF were worth $190,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Invesco Biotechnology & Genome ETF by 78.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,242 shares of the company’s stock valued at $459,000 after acquiring an additional 3,176 shares during the last quarter. Signet Financial Management LLC increased its position in shares of Invesco Biotechnology & Genome ETF by 3.9% during the second quarter. Signet Financial Management LLC now owns 4,351 shares of the company’s stock valued at $279,000 after acquiring an additional 164 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Invesco Biotechnology & Genome ETF by 9.1% during the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 243,959 shares of the company’s stock valued at $15,477,000 after acquiring an additional 20,391 shares during the last quarter. Millstone Evans Group LLC increased its position in shares of Invesco Biotechnology & Genome ETF by 75.8% during the first quarter. Millstone Evans Group LLC now owns 1,684 shares of the company’s stock valued at $107,000 after acquiring an additional 726 shares during the last quarter. Finally, Banque Cantonale Vaudoise purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the first quarter valued at approximately $34,000.

Invesco Biotechnology & Genome ETF Trading Up 2.2%

Shares of NYSEARCA PBE opened at $74.83 on Monday. The stock has a fifty day simple moving average of $70.92 and a two-hundred day simple moving average of $66.45. Invesco Biotechnology & Genome ETF has a 1-year low of $54.52 and a 1-year high of $74.85. The firm has a market cap of $234.22 million, a price-to-earnings ratio of 20.44 and a beta of 0.79.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.